Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	267.81B
Revenue (ttm)	91.34B
Net Income (ttm)	980.70M
Shares Out	1.33B
EPS (ttm)	0.73
PE Ratio	275.20
Forward PE	152.80
Dividend	0.14 (0.07%)
Ex-Dividend Date	Jul 16, 2025

Volume	7,411,786
Average Volume	3,561,089
Open	197.67
Previous Close	197.67
Day's Range	195.50 - 206.60
52-Week Range	181.73 - 307.90
Beta	0.08
RSI	55.99
Earnings Date	Oct 28, 2025

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 5,476
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In 2024, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.